Abstract:Objective To retrospectively analyze anticoagulant effect of bivalirudin and heparin in the patients with coronary heart disease(CHD) and end-stage renal disease(ESRD)during percutaneous coronary intervention(PCI). Methods A total of 62 patients with CHD complicated with ESRD were selected for the study, who received PCI treatment in Wuhan Puren Hospital from October 2015 to December 2018. According to the different anticoagulants administered during operation, they were divided into control group (heparin, n=29) and observation group (bivalirudin, n=33). The two groups were compared in contrast-induced nephropathy (CIN) during hospitalization, net adverse clinical events (NACE) and major adverse cardiac and cerebrovascular events (MACCE) in 30 days and 1 year after operation. The difference of MACCE sub-indexes between the two groups was observed. SPSS statistics 25.0 was used for data analysis, and t-test or Chi-square test was used for comparison between groups. Results During hospitalization, 3 patients developed CIN in both groups without significant difference (P>0.05). At 30 days after the operation, NACE and all bleeding events in the observation group were lower than those in the control group, and the differences were significant (P<0.05). There was no significant difference in MACCE between the two groups (P>0.05). At postoperative 1 year, NACE was significantly lower in the observation group than the control group (P<0.05), and there was no significant difference in MACCE and all bleeding events between the two groups (P>0.05). Conclusion Bivalirudin reduces the NACE and all bleeding events more significantly than heparin within 30 days after PCI in CHD patients with ESRD, showing better anticoagulant effect. The advantage of risk reduction of NACE may last till 1 year after PCI. Bivalirudin is more suitable for anticoagulation in patients with CHD and ESRD during PCI.